scholarly journals Interferon Lambda 4 Polymorphism Predicts Sustained Viral Response in Hepatitis C Virus Patients Irrespective of Hepatitis C Virus Genotypes, Ethnicity or Treatment Regimen: Results From a Meta-Analysis

2015 ◽  
Vol 15 (12) ◽  
Author(s):  
Qin Wu ◽  
Cong Wang ◽  
En Qiang Chen ◽  
Hong Tang ◽  
Zhen Zhen Li ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Treatment Regimen ◽  
Meta Analysis ◽  
Sustained Viral Response ◽  
Viral Response ◽  
Interferon Lambda ◽  
Virus Genotypes ◽  
Hepatitis C Virus Genotypes

scholarly journals Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3

Hepatology ◽  
2015 ◽  
Vol 63 (1) ◽  
pp. 63-73 ◽  
Author(s):  
Kai-Henrik Peiffer ◽  
Lisa Sommer ◽  
Simone Susser ◽  
Johannes Vermehren ◽  
Eva Herrmann ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Interferon Lambda ◽  
Virus Genotypes ◽  
Hepatitis C Virus Genotypes

scholarly journals Mysterious Linkages Between Hepatitis C Virus Genotypes, Interleukin-28B Genotypes and Viral Clearance- A Meta-Analysis

2014 ◽  
Vol 14 (3) ◽  
Author(s):  
Seyed Hossein Aalaei-Andabili ◽  
Bita Behnava ◽  
Shima Salimi ◽  
Heidar Sharafi ◽  
Seyed Moayed Alavian
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Meta Analysis ◽  
Viral Clearance ◽  
Interleukin 28B ◽  
Virus Genotypes ◽  
Hepatitis C Virus Genotypes

Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis

2008 ◽  
Vol 14 (8) ◽  
pp. 1139-1148 ◽  
Author(s):  
Serena Slavenburg ◽  
Ines Weggelaar ◽  
Martijn GH van Oijen ◽  
Joost PH Drenth
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Meta Analysis ◽  
Optimal Length ◽  
Virus Genotypes ◽  
Hepatitis C Virus Genotypes

scholarly journals The Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-Analysis

2016 ◽  
Vol 16 (9) ◽  
Author(s):  
Hossein Ghaderi-Zefrehi ◽  
Mohammad Gholami-Fesharaki ◽  
Heidar Sharafi ◽  
Farzin Sadeghi ◽  
Seyed Moayed Alavian
Keyword(s):  
Systematic Review ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Meta Analysis ◽  
Middle Eastern ◽  
Virus Genotypes ◽  
Hepatitis C Virus Genotypes

Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1

2016 ◽  
Vol 25 (1) ◽  
pp. 15-24 ◽  
Author(s):  
Tim Zimmermann ◽  
Dietrich Hueppe ◽  
Stefan Mauss ◽  
Peter Buggisch ◽  
Heike Pfeiffer-Vornkahl ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Interferon Alpha ◽  
Virological Response ◽  
Sustained Viral Response ◽  
Pegylated Interferon ◽  
Genotype 1 ◽  
Pegylated Interferon Alpha ◽  
Viral Response

Background & Aims: Smoking has multiple effects on factors influencing hepatitis C and antiviral therapy, including lipid metabolism, fibrosis, platelet count and adherence aspects. The aim of this analysis was to determine the impact of smoking on hepatitis C virus antiviral therapy. Methods: Data of two cohorts of an observational multicenter study including therapy-naïve patients infected with genotype 1 hepatitis C virus (HCV) treated with dual antiviral therapy (n=7,796) with pegylated interferon alpha 2a in combination with ribavirin, or triple antiviral therapy (n=1,122) containing telaprevir or boceprevir, were analysed. Results: In the univariate matched pair analysis of dual antiviral therapy patients (n=584), smoking was significantly associated with lower sustained viral response rates (p=0.026, OR 0.69 CI: 0.50 – 0.96). The effect of smoking on sustained viral response remained significant (p=0.028, OR 0.67 CI: 0.47 – 0.96) in the multivariate analysis when adjusting for all other baseline parameters with a significant association in the univariate analysis, i.e. diabetes, fibrosis, body mass index, transaminases and baseline viral load. Under protease inhibitors the influence of smoking on virological response did not arise. Conclusions: Smoking has a negative impact on antiviral therapy in naïve patients infected with HCV genotype 1 independently of age, gender, history of drug use or alcoholic liver disease. The effects of smoking might be overcome by the new antiviral agents.Abbreviations: APRI: AST to platelet ratio index; DAA: direct antiviral agent; DT: dual antiviral therapy; EoTR: end of treatment response; RVR: rapid virological response; EVR: early virological response; HCV: hepatitis C virus; IFN: interferon alpha; MPA: Matched Pair Analysis; NS: non-smokers; PEG-IFN: pegylated interferon alpha 2a; PI: protease inhibitor; RBV: ribavirin; SAE: serious adverse event; SOC: standard of care; S: smokers; SVR: sustained viral response.    

Sign in / Sign up

Export Citation Format

Share Document